Skip to content

A clinical study on the Regulation of Intestinal Microenvironment in coIX Lachana Fujiang Powder for the prevention and Treatment of malignant neoplasia in advanced colorectal adenoma

A clinical study on the Regulation of Intestinal Microenvironment in coIX Lachana Fujiang Powder for the prevention and Treatment of malignant neoplasia in advanced colorectal adenoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003703
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-09-24
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal adenoma

Interventions

Sponsors

Shuguang Hospital affillated with Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Progressive colonic adenoma with clear pathological diagnosis refers to adenoma with > 25% villous structure diameter >=10 mm or adenoma with high-grade intraepithelial neoplasia, which meets one of the above conditions; 2. Aged between 18 and 75 years; 3. The TCM syndrome type conforms to the syndrome of dampness accumulation of spleen deficiency and stagnation of blood stasis and heat, and is intended to be treated with TCM; 4. Did not take antibiotics, aspirin, immunosuppressants and other drugs within three months; 5. no serious heart, liver, kidney, hematopoietic system diseases or other factors affecting drug evaluation; 6. The diet is relatively stable, can complete the questionnaire, and voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with digestive tract diseases, metabolic diseases, cardiovascular diseases, liver diseases, neurological diseases and autoimmune diseases; 2. Take yogurt or probiotics regularly for a long time (2-3 times per week, more than 6 months); 3. Pregnant and lactating women; 4. Allergic to certain drugs in the prescription of Chinese medicine; 5. Have joined other clinical researchers; 6. The researcher considers it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
recurrence rate;

Countries

China

Contacts

Public ContactSui Hua

Shuguang Hospital affillated with Shanghai University of TCM

syh0808@163.com+86 15800492949

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026